Recent Updates — TECX

Tectonic Therapeutic reported a net loss of $21.3 million for the third quarter ended September 30, 2026, compared to a $19.0 million loss in the prior-year period. The company raised approximately $22.3 million in net proceeds from an at-the-market equity offering during the quarter. Cash and cash equivalents totaled $234.7 million as of September 30, 2026, providing a runway into the first quarter of 2029. Clinical updates include favorable Phase 1a safety data for TX2100, FDA Fast Track designation for HHT, dosing of the first patient in the ALPINE Phase 2a trial for TX45, and expected topline results from the APEX Phase 2 trial by January 2027. Tectonic Therapeutic is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors.

Tectonic Therapeutic announced favorable Phase 1a safety, tolerability, and pharmacokinetic results for TX2100 in healthy volunteers. The U.S. FDA granted Fast Track designation for TX2100 to treat Hereditary Hemorrhagic Telangiectasia (HHT) and cleared the Investigational New Drug application for a Phase 1b trial. The company plans to initiate an open-label Phase 1b trial by year-end 2026 and a Phase 2 trial in early 2027. Tectonic Therapeutic is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors.

Tectonic Therapeutic reported a net loss of $22.3 million for the second quarter ended June 30, 2026, compared to a $20.0 million loss in the prior year period. Cash and cash equivalents stood at $227.1 million as of June 30, 2026, providing an expected runway into Q1 2029. The company completed enrollment in its Phase 2 APEX clinical trial for TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), with topline results anticipated in early Q1 2027. Additionally, dosing of single-dose cohorts was completed in the Phase 1a trial for TX2100 targeting Hereditary Hemorrhagic Telangiectasia (HHT), with top-line data expected by the end of Q3 2026. Tectonic Therapeutic is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors.